-
Investigators at the National Institutes of Health have identified a genetic mutation in three unrelated families that causes a rare immune disorder characterized by excessive and impaired immune function. Symptoms of this condition include immune deficiency, autoimmunity, inflammatory skin disorders and cold-induced hives, a condition known as cold urticaria.
National Institute of Allergy and Infectious Diseases (Immunology) - Mon, 16 January 2012
http://www.niaid.nih.gov/
-
Patients hospitalized for autoimmune disorders, like rheumatoid arthritis or Crohn's disease, may be at greater risk for a life-threatening pulmonary embolism, a clot in a main artery of the lung, a new study finds. Reporting online Nov. 25 in The Lancet, researchers warned that steps should be taken to prevent this condition among patients admitted to the hospital for autoimmune diseases.
Medline Plus (Immunology) - Mon, 28 November 2011
http://www.nlm.nih.gov/medlineplus
-
The 2011 Nobel Prize in Physiology or Medicine was divided, one half jointly to Bruce A. Beutler and Jules A. Hoffmann "for their discoveries concerning the activation of innate immunity" and the other half to Ralph M. Steinman "for his discovery of the dendritic cell and its role in adaptive immunity".
Nobelprize.org (Immunology) - Tue, 4 October 2011
http://www.nobelprize.org
-
Random patterns of deamination by the enzyme activation-induced deoxycytidine deaminase (AID) are the key to generating antibody diversity, a crucial component to a healthy immune system, according to a new study by USC Dornsife researchers published in The Journal of Biological Chemistry.
University of Southern California (Immunology) - Mon, 4 July 2011
http://www.usc.edu
-
The U.S. Food and Drug Administration on Wednesday gave lupus patients their first new treatment option in more than 50 years when it approved Benlysta as a way to ease the painful symptoms of this debilitating autoimmune disorder. Injected directly into a vein, Benlysta is the first drug designed to target a protein that may reduce the number of abnormal B cells believed to be at the root of lupus, the FDA said in a news release. The last lupus drugs approved by the agency were Plaquenil (hydroxychloroquine) and corticosteroids; both were given the agency's blessing in 1955. Back in 1948, aspirin was approved to treat the disease. Lupus strikes women far more often than men, and symptoms typically first appear between the ages of 15 and 44. The joints, skin, kidneys, lungs, heart and brain can all be affected, and when symptoms flare up they include swelling in the joints or joint pain, light sensitivity, fever, chest pain, hair loss and fatigue, the FDA said.
Medline Plus (Immunology) - Mon, 14 March 2011
http://www.nlm.nih.gov/medlineplus
-
Allergies and autoimmune diseases such as rheumatoid arthritis could one day be prevented by consuming a type of bacteria, like probiotics taken in yoghurt, according to a study published on Friday.
MedNews (Immunology) - Tue, 28 December 2010
http://mn.medsurfnews.com/
-
The relationship between infection and autoimmunity has been increasingly defined over the past 20 years. Bacterial, viral and parasitic infections are known to induce and exacerbate autoimmune diseases, mainly by the mechanism of molecular mimicry.
Rheumatology (Immunology) - Tue, 31 August 2010
http://rheumatology.oxfordjournals.org/
-
The approval by the World Health Organization of a low cost vaccine against meningitis has been hailed by the charity Médecins Sans Frontières as a move "full of promise" for the 430 million people at risk of the disease in the meningitis belt of sub-Saharan Africa.
British Medical Journal (Immunology) - Mon, 5 July 2010
http://www.bmjjournals.com
-
Following a review of the latest data on pandemic influenza A (H1N1) 2009 vaccines, WHO's Strategic Advisory Group of Experts (SAGE) on Immunization, has concluded that its previous recommendations on priority target groups and number of doses still stand.
World Health Organization (Immunology) - Mon, 31 May 2010
http://www.who.int
-
Vaccines against seasonal influenza available in the USA are of two kinds: the inactivated one, to be administered intramuscularly, and the live attenuated one, to be nasally nebulized. Now, the results of a double-blinded trial, performed in Michigan during 2007-2008 seasonal influenza, sponsored by the producer of the inactivated vaccine, have been published.
MedNews (Immunology) - Tue, 18 May 2010
http://mn.medsurfnews.com/